Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study

BACKGROUND: Metastasized or unresectable melanoma has been the first malignant tumor to be successfully treated with checkpoint inhibitors. Nevertheless, about 40–50% of the patients do not respond to these treatments and severe side effects are observed in up to 60%. Therefore, there is a high need...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Forschner, Andrea, Battke, Florian, Hadaschik, Dirk, Schulze, Martin, Weißgraeber, Stephanie, Han, Chung-Ting, Kopp, Maria, Frick, Maximilian, Klumpp, Bernhard, Tietze, Nicola, Amaral, Teresa, Martus, Peter, Sinnberg, Tobias, Eigentler, Thomas, Keim, Ulrike, Garbe, Claus, Döcker, Dennis, Biskup, Saskia
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6625062/
https://ncbi.nlm.nih.gov/pubmed/31300034
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0659-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados